Inappropriate Sinus Tachycardia Registry
Key facts
- Where
- Warsaw, PolandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT05107635, who can take part
Where in Poland
- Central Clinic HospitalWarsaw, PolandContact: Monika PawelecTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AtriCure, Inc.
- Trial code
- NCT05107635
- Record updated
- 7 October 2026
- Original description
The primary objective of this registry is to capture real-world safety and performance data on AtriCure devices used to ablate cardiac tissue when treating Inappropriate Sinus Tachycardia (IST) or Postural Tachycardia Syndrome (POTS). This is a retrospective and prospective, multicenter, US/OUS, observational data registry.Read full original descriptionShow less
A Multicenter Patient Registry for Outcomes of Inappropriate Sinus Tachycardia and Postural Orthostatic Tachycardia Syndrome Treatment
The primary objective of this registry is to capture real-world safety and performance data on AtriCure devices used to ablate cardiac tissue when treating Inappropriate Sinus Tachycardia (IST) or Postural Tachycardia Syndrome (POTS). This is a retrospective and prospective, multicenter, US/OUS, observational data registry.
Inclusion: Subject is scheduled to undergo or has undergone a procedure to treat IST or POTS using one or more AtriCure devices; Subject is willing to provide written informed consent (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this Registry) or authorization per institution and geographical requirements.
Exclusion: Subject is enrolled in a concurrent study that may impact treatment outcome of IST or POTS; Subject with exclusion criteria required by FDA or local governance.